• Immunogenicity Assessment

    • Therapeutic In Silico Services
      • ISPRIâ„¢ Website
      • ISPRI Downselectâ„¢
      • ISPRI Quantifyâ„¢
      • ISPRI Analyzeâ„¢
      • ISPRI Evaluateâ„¢
      • ISPRI-HCPâ„¢
      • ISPRI Designâ„¢
      • PANDA® Screening
    • Vaccine In Silico Services
      • iVAXâ„¢
      • EpiCCâ„¢
      • Ancer®
      • PreVAXâ„¢
    • Lab Services
      • HLA Binding Assay
      • Naive CD4+ T Cell Assay
      • Innate Assay
    • Consulting Services
  • About Us
    • Leadership
    • Careers
  • Partner
  • Press
    • News
    • Events
    • Publications
    • Blog
  • Contact Us
Structure-guided Immunogen Design: Modulating B cell and T cell Immunogenicity of First and Second Generation H7N9 Vaccines

Structure-guided Immunogen Design: Modulating B cell and T cell Immunogenicity of First and Second Generation H7N9 Vaccines

by Annie De Groot | Mar 20, 2019

ACVR immune engineering poster 2019_20Mar2019_930am
T cell epitope engineering: an avian H7N9 influenza vaccine strategy for pandemic preparedness and response

T cell epitope engineering: an avian H7N9 influenza vaccine strategy for pandemic preparedness and response

by Annie De Groot | Aug 15, 2018

T cell epitope engineering: an avian H7N9 influenza vaccine strategy for pandemic preparedness and response

T-cell epitope content comparison (EpiCC) of swine H1 influenza A virus hemagglutinin

by Sarah Moniz | Dec 19, 2017

Considerations for the rapid deployment of vaccines against H7N9 influenza

Considerations for the rapid deployment of vaccines against H7N9 influenza

by Adam | Oct 22, 2016

Considerations for the rapid deployment of vaccines against H7N9 influenza. University of Melborne. Expert Rev Vaccines. 2014 Jul 12
Immunoinformatic comparison of T-cell epitopes contained in novel swine-origin influenza A (H1N1) virus with epitopes in 2008-09 Conventional Influenza Vaccine

Immunoinformatic comparison of T-cell epitopes contained in novel swine-origin influenza A (H1N1) virus with epitopes in 2008-09 Conventional Influenza Vaccine

by Adam | Oct 22, 2016

Vaccine. 2009 Sep 25;27(42):5740-7. PMID: 19660593.
« Older Entries
Next Entries »

Recent Posts

  • The Platinum Vaccine & Change is Good!
  • EpiVax Appoints Dr. Vibha Jawa to Lead Scientific Strategy as CSO
  • Smarter Tools, Safer Therapies: Supporting the FDA’s Roadmap with in silico Immunogenicity Assessment
  • The Amsterdam Immunogenicity & Tolerance Seminar: 2025
  • The Westin Immunogenicity Seminar

Recent Comments

No comments to show.

Join our newsletter

Stay up to date with EpiVax and greater industry news, events, and technological advancements with this monthly update written by EpiVax co-founder and CMO, Dr. Annie De Groot.

Explore

Therapeutic In Silico Services

Vaccine In Silico Services

Lab Services

Consulting

LinkedIn

About Us

Careers

Partner

News

Events

Publications

Contact Us

We use cookies to ensure that we give you the best experience on our website. By clicking 'accept', you consent to our use of cookies.AcceptDecline